Peak6 LLC Purchases New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Peak6 LLC acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $251,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $96,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at $97,000. Covestor Ltd boosted its holdings in Intra-Cellular Therapies by 15.9% in the fourth quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock valued at $175,000 after acquiring an additional 288 shares during the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new stake in Intra-Cellular Therapies in the fourth quarter worth about $184,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Tuesday. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The business’s 50 day simple moving average is $130.84 and its 200 day simple moving average is $106.85. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on ITCI. StockNews.com began coverage on shares of Intra-Cellular Therapies in a research report on Monday. They set a “hold” rating for the company. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Cantor Fitzgerald restated a “neutral” rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Finally, Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Eleven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of “Hold” and an average price target of $109.70.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.